Shelf life (days): 1460.0
Formulation: A solid
Formal Name: 2-[3-cyano-4-[2-(methyl-d3)propoxy-1,1,2,3,3,3-d6]phenyl]-4-methyl-5-thiazolecarboxylic acid
Purity: ≥99% deuterated forms (d1-d9)
Formula Markup: C16H7D9N2O3S
Formula Weight: 325.43046
CAS Number: 1246819-50-0
Notes: Febuxostat-d9 is intended for use as an internal standard for the quantification of febuxostat (Item No. 14127) by GC- or LC-MS. Febuxostat is an antihyperuricemic nonpurine inhibitor of both the oxidized and reduced forms of xanthine oxidase.{22476} It inhibits bovine milk xanthine oxidase as well as mouse and rat liver xanthine oxidase/xanthine dehydrogenase (IC50s = 1.4, 1.8, and 2.2 nM, respectively).{42215} It is 10-30 times more potent than the hypoxanthine analog allopurinol (Item No. 10012597; Kis = 0.7 nM and 0.7 μM, respectively).{22474,22475} Febuxostat decreases the serum level of urate in a potassium oxonate rat model of hyperuricemia (ED50 = 1.5 mg/kg).{42215} It reduces hepatic macrovesicular steatosis in mice fed a high-fat diet containing trans fatty acids when administered at a dose of 1 mg/kg per day.{43642} Febuxostat (0.75 mg/kg) also increases CNS expression of glutamate oxaloacetate transaminase 2 (GOT2) and improves neurological symptoms in a mouse model of secondary progressive experimental autoimmune encephalomyelitis (EAE).{42216} Formulations containing febuxostat have been used in the treatment of symptomatic hyperuricemia in patients with gout.
English
Deutsch
